JP2011510985A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510985A5
JP2011510985A5 JP2010545031A JP2010545031A JP2011510985A5 JP 2011510985 A5 JP2011510985 A5 JP 2011510985A5 JP 2010545031 A JP2010545031 A JP 2010545031A JP 2010545031 A JP2010545031 A JP 2010545031A JP 2011510985 A5 JP2011510985 A5 JP 2011510985A5
Authority
JP
Japan
Prior art keywords
chloro
pyridin
imidazo
ethylpropyl
chemical entity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010545031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000686 external-priority patent/WO2009099594A1/en
Publication of JP2011510985A publication Critical patent/JP2011510985A/ja
Publication of JP2011510985A5 publication Critical patent/JP2011510985A5/ja
Withdrawn legal-status Critical Current

Links

JP2010545031A 2008-02-04 2009-02-02 特定の化学的実体、組成物および方法 Withdrawn JP2011510985A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2606708P 2008-02-04 2008-02-04
PCT/US2009/000686 WO2009099594A1 (en) 2008-02-04 2009-02-02 Certain chemical entities, compositions and methods

Publications (2)

Publication Number Publication Date
JP2011510985A JP2011510985A (ja) 2011-04-07
JP2011510985A5 true JP2011510985A5 (enExample) 2012-03-08

Family

ID=40952391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545031A Withdrawn JP2011510985A (ja) 2008-02-04 2009-02-02 特定の化学的実体、組成物および方法

Country Status (18)

Country Link
US (2) US7989469B2 (enExample)
EP (1) EP2244711A4 (enExample)
JP (1) JP2011510985A (enExample)
KR (1) KR20100119773A (enExample)
CN (1) CN101983061A (enExample)
AR (1) AR072242A1 (enExample)
AU (1) AU2009210787A1 (enExample)
BR (1) BRPI0907502A2 (enExample)
CA (1) CA2713864A1 (enExample)
CL (1) CL2009000246A1 (enExample)
CO (1) CO6290673A2 (enExample)
EA (1) EA201001224A1 (enExample)
EC (2) ECSP10010430A (enExample)
IL (1) IL207367A0 (enExample)
MX (1) MX2010008518A (enExample)
TW (1) TW200946524A (enExample)
WO (1) WO2009099594A1 (enExample)
ZA (1) ZA201005780B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
MX2010008518A (es) * 2008-02-04 2010-11-10 Cytokinetics Inc Ciertas entidades quimicas, composiciones y metodos.
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
US8927572B2 (en) 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
WO2013010015A2 (en) 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
CN104395458A (zh) * 2012-04-11 2015-03-04 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力
EP3137622B1 (en) 2014-04-29 2021-11-24 Cytokinetics, Inc. Methods of reducing decline in vital capacity
TW201927738A (zh) * 2017-12-14 2019-07-16 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物
TWI794369B (zh) * 2017-12-14 2023-03-01 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物
JP7592029B2 (ja) 2019-05-28 2024-11-29 マンカインド ファーマ リミテッド ヤヌスキナーゼ1の阻害のための新規化合物
KR20240024062A (ko) * 2021-05-06 2024-02-23 엑스사이언티아 에이아이 리미티드 Pkc-세타 조정제
CN118702622A (zh) * 2024-08-30 2024-09-27 阜新达得利化工股份有限公司 一种3-溴-2-氰基吡啶的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
CA2550091A1 (en) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1959962A2 (en) * 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
EP2666777A1 (en) 2006-08-02 2013-11-27 Cytokinetics, Inc. Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
EP2139478A4 (en) * 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
MX2010008518A (es) * 2008-02-04 2010-11-10 Cytokinetics Inc Ciertas entidades quimicas, composiciones y metodos.
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法

Similar Documents

Publication Publication Date Title
JP2011510985A5 (enExample)
JP6731463B2 (ja) 新規の二環式ブロモドメイン阻害剤
JP6461263B2 (ja) C−fmsおよび/またはc−kit活性を調節する化合物およびその用途
AU2015365465B2 (en) Amido thiadiazole derivatives as NADPH Oxidase inhibitors
TWI730959B (zh) 作為激酶抑制劑之雜環醯胺
CA2915561C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
JP5555620B2 (ja) オキサゾールチロシンキナーゼ阻害剤
JP4533534B2 (ja) グリコーゲンシンターゼキナーゼ3のインヒビター
Martorana et al. Heterocyclic scaffolds for the treatment of Alzheimer’s disease
JP2016164184A5 (enExample)
JP2016507496A (ja) ブロモドメイン阻害剤としての新規複素環式化合物
JP2013544840A5 (enExample)
KR20100101056A (ko) 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
JP2016534023A5 (enExample)
EP2477629A1 (en) Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2019505594A5 (enExample)
JP2006522137A (ja) 代謝型グルタミン酸受容体−5のジ−アリール置換ピロールモジュレーター
JP2017519818A5 (enExample)
RU2014132044A (ru) Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
JP2020503302A5 (enExample)
JP2007223901A (ja) 複素環化合物およびその用途
JP2018522062A5 (enExample)
JP7046250B2 (ja) がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ
EP3628669A1 (en) Novel compounds as nadph oxidase inhibitors